Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short

Group 1 - Eli Lilly reported net income of $4.41 billion, or $4.88 per share, on revenue of $13.53 billion, which was slightly below analyst expectations of $4.52 billion in profit and $13.56 billion in revenue [1] - Adjusted earnings per share (EPS) of $5.32 exceeded expectations of $5.11, indicating strong performance despite overall results being worse than expected [1] - Sales of weight-loss drugs Mounjaro and Zepbound reached $3.53 billion and $1.91 billion, respectively, falling short of expectations of $3.65 billion and $2.04 billion [2] Group 2 - Eli Lilly expects 2025 revenue to be between $58.0 billion and $61.0 billion, with EPS projected from $22.05 to $23.55, and adjusted EPS from $22.50 to $24.00, which aligns with or exceeds market expectations [2] - Following the earnings report, Eli Lilly shares rose more than 2%, reflecting positive market sentiment, while the stock has increased approximately 20% over the past year [3] - In contrast, rival Novo Nordisk's shares have declined about 25% in the past year, highlighting a competitive landscape in the weight-loss drug market [3]